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1. Policy 2005-01
Continuation of Drug Therapy Upon 
Discontinuance of a Practitioner’s  
Practice – A Joint Policy of the Department 
of Public Health, Drug Control Program and 
Board of Registration in Pharmacy
When a pharmacist becomes aware that a practitioner, 
or other person authorized to prescribe in accordance with 
M.G.L. c. 94C, has ceased to practice for any reason and 
that the practitioner-patient relationship has ended, existing 
drug therapy may still need to be continued. Therefore, a 
pharmacist may, pursuant to a prescription previously issued 
by that practitioner or other authorized prescriber and in the 
exercise of good professional judgment, dispense remaining 
refills of a prescription up to a maximum 90-day supply, to 
enable the patient to establish a relationship with another 
practitioner. Refills authorized pursuant to this policy may 
not be dispensed in quantities greater than a 30-day supply 
in a single filling, except where patient insurance coverage 
requires dispensing of a 60- or 90-day supply.
2. Letter from the President
By George A. Cayer, RPh 
It is truly an honor to serve as president of the Massa-
chusetts Board of Registration in Pharmacy for 2006. The 
practice of pharmacy is always changing and 2006 will be 
no different. Some of the opportunities and challenges facing 
the Board under my presidency this year are: 
a. Ongoing education of pharmacists regarding the imple-
mentation of continuous quality improvement (CQI) 
program requirements of 247 Code of Massachusetts 
Regulation 15.00. Quality must be the focal point of all 
licensed pharmacies in Massachusetts; 
b. Ongoing education of the important role pharmacy 
technicians have in supporting pharmacists in every 
patient setting;
c. supporting Collaborative Drug Therapy Management 
concepts; and
d. ongoing education to consumers and pharmacists regarding 
new laws for dispensing emergency contraception (EC).
I ask all Massachusetts pharmacists to closely examine 
their evolving responsibilities in the health care system. 
The role of pharmacists continues to expand and we 
should all embrace the changes and be aware of these 
new responsibilities. In the coming year, I ask all of you 
to identify one major issue of importance to your practice 
and become more personally involved with it. Together, 
we can make the practice of pharmacy all that it is meant 
to be and improve our professional image in the communi-
ties we serve.
3. Clarification of Technician 
Registration Requirements 
Since registration issues involving certain individuals em-
ployed as pharmacy technicians in Massachusetts pharma-
cies continue, the Board believes it is necessary to reiterate 
the message that appeared in the April 2005 Newsletter. 
All individuals employed as pharmacy technicians 
in the Commonwealth must (after completing required 
training and examination) file an application for registra-
tion as a pharmacy technician with the Board. Every two 
years after the initial registration period, all pharmacy 
technicians are required to file a renewal application 
with the Board. Please be reminded that Pharmacy Tech-
nician Certification Board (PTCB) certification is not the 
equivalent of the state-mandated requirement of current 
registration with the Board for employment as a pharma-
cy technician in the Commonwealth. The Board is aware 
of individuals who have achieved PTCB certification and 
began employment as technicians without applying for 
registration by the Board, as required by M.G.L. c. 112, 
§24C-24E. Other individuals who have achieved PTCB 
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certification after registering as pharmacy technicians 
with the Board have then failed to renew their technician 
registration with the Board after the initial registration 
period. Since current registration by the Board is statuto-
rily mandated for employment as a pharmacy technician 
in the Commonwealth, any individual employed as a 
pharmacy technician who is not in compliance with state 
laws and Board regulations (247 CMR 8.02-8.07), as well 
as any pharmacist and pharmacy employing such person, 
risks adverse action by the Board and law enforcement 
authorities for unlicensed practice.
4. Joint Guideline for Pharmacist 
Dispensing of Emergency Contraception
The Department of Public Health (Department), specif-
ically the Board of Registration in Pharmacy (Pharmacy 
Board), the Board of Registration in Medicine and the 
Drug Control Program under authority of M.G.L. c. 94C, 
have adopted Guidelines (Pharmacy Board Policy No. 
2006-1) that describe the requirements for pharmacists 
to dispense Emergency Contraception (EC) pursuant 
to M.G.L. c. 94C, § 19A in accordance with a written 
standardized procedure or protocol (i.e., Standing Order) 
developed by an actively practicing physician registered 
with the Commissioner to distribute or dispense a con-
trolled substance in the course of professional practice 
pursuant to M.G.L. c. 94C, §7. Pursuant to the statute, 
the Standing Order must be maintained on file at the 
participating pharmacy and a copy filed with the Phar-
macy Board. In addition to requirements for dispensing, 
these Guidelines set forth requirements for training and 
reporting.
Physician Orders Are Required to Dispense EC
Prior to the enactment of Chapter 91 of the Acts of 2005, 
a prescription from an authorized prescriber in compliance 
with Department regulations was required to dispense EC 
(e.g., Plan B).
In accordance with M.G.L. c. 94C, § 19A, a pharmacist 
may now alternatively dispense EC pursuant to a Standing 
Order developed by an actively practicing registered phy-
sician (see the Guidelines below). Standing Orders must 
include written, standardized procedures and protocols; 
the printed name and signature of the physician; and the 
entity(ies) authorized by the Physician. 
A physician may issue a Standing Order for a pharmacist, 
pharmacy or group of pharmacies under common ownership 
or control of one entity. 
Guidelines for Dispensing EC Pursuant to 
Standing Order 
Prerequisites
A pharmacist may dispense EC pursuant to a Standing 
Order of an actively practicing physician who is registered 
with the Commissioner provided that:
a. the pharmacist is currently licensed by the Pharmacy 
Board;
b. the pharmacist has completed training accredited by 
the Accreditation Council [for] Pharmacy Education 
(ACPE) or offered by an “Approved College or School 
of Pharmacy” (247 CMR 2.00), which training shall 
include instruction on:
1. referring patient for additional service and follow-up;
2. quality assurance; and
3. proper documentation. 
c. the Standing Order is maintained on file (readily retriev-
able) at the pharmacy; and 
d. a copy of the Standing Order has been filed with the 
Pharmacy Board.
Training
Proof of training must be on file (readily retrievable) at 
the pharmacy.
Filing
A copy of the Standing Order must be maintained on file 
(readily retrievable) at each participating pharmacy site.
One copy of the Standing Order must be filed with the 
Board. Where a Standing Order provided to the participating 
pharmacy includes a certification that the Order has been 
filed with the Board, it is not necessary to make duplicate 
filings with the Board.
Offer to Provide Medication Counseling
As currently required by M.G.L. c. 94C and Pharmacy 
Board regulations 247 CMR.
Required Reporting
In accordance with M.G.L. c. 94C, § 19A(d), annual re-
porting of dispensings is required. Where possible, reports 
shall aggregate the total number of units of use dispensed 
pursuant to a Standing Order (not including units of use 
dispensed pursuant to a prescription). Reports are not 
public records and shall not include any patient names or 
identifiers. 
Annual reports must be electronically submitted to the 
Department not later than August 1st for the period from 
July 1 through June 30 of the prior year. 
An authorized representative for a group of pharmacies 
under common ownership or control of one entity may 
report on behalf of all pharmacies, provided subtotals 
are submitted for each location by permit number (and 
zip code). 
A reporting format will be available on the Department’s 
website.
Reports shall be submitted electronically to the Depart-
ment. Instructions will be provided on the Department’s 
website.
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5. Massachusetts Professional 
Recovery Program
Program for Chemically Dependent 
Pharmacists and Allied Health Professionals
“Licensed professionals reaching out to help other licensed 
professionals cope with alcohol and drug problems.”
For confidential information please contact the Massachu-
setts Professional Recovery Program (MPRS) Coordinator 
Tim McCarthy at 617/973-0910 or visit the MPRS Web site 
at www.mass.gov/dpl/services/mprs.htm.
6. Frequently Asked Questions About 
Implementation of Chapter 91 of 
the Acts of 2005 ‘Timely Access to 
Emergency Contraception’ (March 2006)
Pharmacy Training, Filing, and Practice
1. Question: Is a pharmacist required to provide EC to a 
pharmacy customer who does not have a prescription? 
 Answer: No. 
Dispensing under a standing order is voluntary. In accor-
dance with M.G.L. c. 94C, §19A, a trained pharmacist may 
now alternatively dispense EC pursuant to a standing order 
developed by an actively practicing registered physician. 
See Board Policy No. 2006-1.
Prior to the enactment of Chapter 91 of the Acts of 2005, 
a prescription from an authorized prescriber in compliance 
with Department regulations was required to dispense EC.
2. Question: Can a pharmacist dispense Plan B pursuant to 
a standing order if he or she completed training required 
by M.G.L. c. 94C §19(A)(c) prior to implementation of 
the law on December 14, 2005? (Or, does the pharmacist 
need further training?)
 Answer: Generally, yes if the pharmacist has completed 
the substantive training prerequisites. 
The new law specifies training content areas that must be 
mastered prior to a pharmacist dispensing EC per a standing 
order. Board Policy No. 2006-1 requires that proof of training 
must be on file (readily retrievable) at the pharmacy.  
Those pharmacists who received training prior to De-
cember 14, 2005, are advised to consult with ACPE or the 
approved college or school of pharmacy where the pharma-
cist received training to make sure that such institution has 
provided the pharmacist with requisite proof of training on 
the following topics: 
 Referring patient for additional service and follow-up; 
 Quality assurance; and 
 Proper documentation.
If the certificate of completion issued by ACPE or the 
approved college or school of pharmacy is dated before 
December 14, 2005, ACPE or the approved college or 
school of pharmacy that issued the certificate of completion 
may provide the pharmacist with additional documentation 
on its letterhead that clarifies that the training offered on a 
specific date covering the topics required by Board Policy 
No. 2006-1. 
If the pharmacist does not have requisite proof of training 
from ACPE or the approved college or school of pharmacy 
where he or she received training or the training curriculum 
did not cover requisite topics, the pharmacist is advised to 
seek further training to document that he or she possesses 
requisite qualifications. 
3. Question: If a pharmacist works in multiple locations, 
as a “floater,” does the pharmacist need proof of training 
to be readily retrievable in each location (or just in his 
or her home location)?
 Answer: Yes.  A pharmacist must have proof of training 
readily retrievable at each location in which the phar-
macist dispenses EC pursuant to a standing order.  
The best practice is for the pharmacist to file a hard 
copy of the training certificate with each work site so 
that the pharmacy may make such proof available to 
Massachusetts Department of Public Health (MDPH) 
inspectors upon request. Alternatively, if the pharmacy 
where the pharmacist works can readily retrieve or 
download a copy of training certificate(s) of completion 
via the Internet (using a unique identifier assigned by an 
approved college of pharmacy), or any other electronic 
means of transmitting proof of training, such as by fax 
or e-mail attachment, maintenance of a hard copy at each 
work site is not necessary.
4. Question: How will a pharmacist know that a particular 
standing order signed by a particular physician has been 
filed with the Board of Registration in Pharmacy and is 
ready for use? 
 Answer: See best practice suggestion(s) for physicians 
(Question No. 9 below).
5. Question: If a pharmacy has a standing order on file 
at the pharmacy and at the Board of Registration in 
Pharmacy that authorizes the dispensing of Plan B per 
the standing order by any qualified pharmacist practic-
ing at that location, must all pharmacists who practice 
at that pharmacy location dispense Plan B under the 
standing order?
 Answer: No. 
The new state law on timely access to EC does not re-
quire all pharmacists employed at a particular location to 
dispense under a standing order. Conditions of employment 
and scheduling of shifts of pharmacists who opt to partici-
pate are matters left to the management prerogative of the 
employer.
6. Question: Is it necessary for minors (persons under age 
18) to obtain parental consent to obtain EC medication 
from a pharmacist or pharmacy that is authorized to 
dispense under a standing order?
Page 4
National Pharmacy Compliance News
(Applicability of the contents of articles in the National Pharmacy Compliance News to a particular state or jurisdiction should not be assumed 
and can only be ascertained by examining the law of such state or jurisdiction.)
FDA Cautions Consumers About Filling US 
Prescriptions Abroad
Food and Drug Administration (FDA) issued a warning to 
health care professionals and consumers that filling their prescrip-
tions abroad may have adverse health consequences due to the 
confusion with drug brand names that could inadvertently lead 
consumers to take the wrong medication for their condition. In 
an investigation, FDA has found that many foreign medications, 
although marketed under the same or similar-sounding brand 
names as those in the United States, contain different active 
ingredients than in the US. Taking a different active ingredient 
could potentially harm the user. 
FDA found 105 US brand names that have foreign counterparts 
that look or sound so similar that consumers who fill such prescrip-
tions abroad may receive a drug with the wrong active ingredient. 
For example, in the United Kingdom, Amyben®, a brand name 
for a drug product containing amiodarone, used to treat abnormal 
heart rhythms, could be mistaken for Ambien®, a US brand name 
for a sedative. Using Amyben instead of Ambien could have a 
serious adverse outcome. For more information on this topic visit 
www.fda.gov/oc/opacom/reports/confusingnames.html.
Safety Can Not be Sacrificed  
For Speed
This column was prepared by the Institute 
for Safe Medication Practices (ISMP). ISMP 
is an independent nonprofit agency that works 
closely with United States Pharmacopeia (USP) 
and FDA in analyzing medication errors, near 
misses, and potentially hazardous conditions as 
reported by pharmacists and other practitioners. ISMP then makes 
appropriate contacts with companies and regulators, gathers ex-
pert opinion about prevention measures, then publishes its recom-
mendations. If you would like to report a problem confidentially 
to these organizations, go to the ISMP Web site (www.ismp.org) 
for links with USP, ISMP, and FDA. Or call 1-800/23-ERROR to 
report directly to the USP-ISMP Medication Errors Reporting 
Program. ISMP address: 1800 Byberry Rd, Huntingdon Valley, 
PA 19006. Phone: 215/947-7797. E-mail: ismpinfo@ismp.org. 
Problem: Typically, pharmacies have developed well-estab-
lished methods for monitoring the accuracy of the dispensing pro-
cess. But today, pharmacy work is increasingly stressful and these 
checks and balances can easily be strained beyond capacity. With 
an increasing number of prescriptions and a shortage of qualified 
pharmacists, conditions are ripe for potentially unsafe working 
conditions – long hours without breaks; multitasking between 
answering phones, overseeing other pharmacy staff, dispensing 
prescriptions, and counseling patients; and ever-increasing time 
spent attending to insurance issues. Inevitably, these conditions 
can increase the chance for dispensing errors.
One pharmacy knows this all too well after a five-year-old boy 
died as a result of an order entry and medication compounding 
error that was not caught by the usual verification process. In this 
case, imipramine was dispensed in a concentration five times 
greater than prescribed. Imipramine is a tricyclic antidepressant 
used to treat adults, but it is also used to treat childhood enuresis. 
An extemporaneous solution was to be prepared at this pharmacy 
that specialized in compounded prescriptions since a liquid for-
mulation was not commercially available. A pharmacy technician 
incorrectly entered the concentration of the prescribed solution 
into the computer as 50 mg/mL instead of 50 mg/5 mL, along 
with the prescribed directions to give 2 tsp at bedtime. He then 
proceeded to prepare the solution using the incorrect concentra-
tion on the label rather than the concentration indicated on the 
prescription. When the compound was completed, the technician 
placed it in a holding area to await a pharmacist’s verification. 
At this time, one of the two pharmacists on duty was at lunch 
and the high workload of the pharmacy made it difficult for the 
pharmacist to check the prescription right away. When the child’s 
mother returned to pick up the prescription, the cash register clerk 
retrieved the prescription from the holding area without telling a 
pharmacist, and gave it to the mother, unaware that it had not yet 
been checked. At bedtime, the mother administered 2 tsp of the 
drug (500 mg instead of the intended 100 mg) to the child. When 
she went to wake him the next morning, the child was dead. An 
autopsy confirmed imipramine poisoning.
There are many factors that contributed to this error includ-
ing inaccurate order entry and issues related to high workload. 
However, a critical breakdown in safety processes occurred when 
the cash register clerk took the prescription from the pharmacy 
holding area (to prevent the mother from waiting any longer for 
the prescription), thereby circumventing the usual pharmacist 
verification process.
While this error underscores a growing problem in health care, 
the problem was clearly evident to this pharmacy owner – even 
a year before the error occurred. When interviewed for an article 
that appeared in a national publication, he vented his frustrations 
about the scant attention paid in our society to pharmacist work-
load difficulties faced in today’s health care environment. On 
the day of the interview, 49 prescriptions were in the process of 
being prepared and about a dozen patients were standing in line 
or wandering around the store waiting for prescriptions. Yet this 
was a slow day. The owner also said that, while managed care 
had reduced profits considerably over the past several years, pre-
scription volume had increased 50% (at the time of the error, the 
pharmacy was dispensing about 10,000 prescriptions per month 
versus 7,000 per month during the prior year, without an increase 
in staff) and medication regimens and drug interactions were more 
complex. To overcome these barriers, the owner added private 
consultation areas for patient counseling; installed a $175,000 
robot that accurately dispenses the 200 most common drugs; 
and diversified sales to offset full-time pharmacists’ salaries. But 
these efforts could not have prevented this tragic fatal error that 
circumvented the normal safety processes.
Safe Practice Recommendations: The environment and 
demands placed on health professionals significantly affect their 
ability to provide safe health care services. While technology such 
as robots can help, overstressed professionals cannot consistently 
perform at the maximum level of safety. Therefore, it is impor-
tant that the public and health care leadership understand this 
problem so they can be more open to tradeoffs, such as working 
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with one patient at a time and incurring longer turnaround times, 
which are necessary to enhance patient safety. With a shortage of 
qualified professionals, we need to demand more rapid adoption 
of computerized prescribing to reduce time spent with prescription 
transcription. We should identify the biggest distractions that occur 
in our workplaces and eliminate or reduce the source by batching 
common interruptions and reorganizing work areas. Staff members 
need to be properly trained to understand safety procedures that 
are in place and know the limits of their specific duties. Fail-safe 
processes to ensure an independent double check before dispensing 
medications and performing other critical processes are a must. The 
pharmacy where this error occurred now requires two pharmacists 
to check every prescription. Unfortunately, this level of vigilance 
is typical after a patient has been harmed from an error. In other 
pharmacies, especially where there is only one pharmacist on duty, 
technicians may be involved in the double-check process.
A few other strategies can be used to prevent similar errors:
	Have one person perform order entry and a different person 
prepare the prescription, if possible, to add an independent 
validation of the order entry process.
	Do not prepare prescriptions using only the computer-generated 
label, as order entry may have been incorrect.
	Ensure that the original prescription, computer-generated la-
bel, prepared product, and manufacturer’s product(s) remain 
together throughout the preparation process.
	Verify dispensing accuracy by comparing the original prescrip-
tion with the labeled patient product and the manufacturer’s 
product(s) used.
NIH Develops Community Drug Alert Bulletin
The National Institute on Drug Abuse, as part of the Na-
tional Institutes of Health (NIH), has developed a new Com-
munity Drug Alert Bulletin that addresses the latest scientific 
research on the non-medical use of prescription drugs of abuse 
and addiction.
This bulletin is geared toward parents, teachers, counselors, 
school nurses, and health professionals who are associated with 
those at risk from prescription drug abuse for non-medical pur-
poses. It summarizes the growing problem in the US and the trend 
of non-medical use of prescription drugs. For more information on 
this bulletin visit www.nida.nih.gov/PrescripAlert/index.html.
Implementation of the Anabolic Steroid 
Control Act of 2004
According to the December 16, 2005 Federal Register, effec-
tive January 20, 2005, the Anabolic Steroid Control Act of 2004 
amended the Controlled Substances Act (CSA) and replaced the 
existing definition of “anabolic steroid” with a new definition. 
This new definition changed the basis for all future administrative 
scheduling actions relating to the control of the anabolic steroids as 
Schedule III controlled substances (CS) by eliminating the require-
ment to prove muscle growth. Also, the Act lists 59 substances as 
being anabolic steroids; these substances and their salts, esters, and 
ethers are Schedule III CS. The Act also revised the language of 
the CSA requiring exclusion of certain over-the-counter products 
from regulation as CS.
According to the House Report, the purpose of the Act is 
“to prevent the abuse of steroids by professional athletes. It 
will also address the widespread use of steroids and steroid 
precursors by college, high school, and even middle school 
students.”
The changes to the definition include the following:
	Correction of the listing of steroid names resulting from the 
passage of the Anabolic Steroid Control Act of 1990.
	Replacement of the list of 23 steroids with a list of 59 steroids, 
including both intrinsically active steroids as well as steroid 
metabolic precursors.
	Automatic scheduling of the salts, esters, and ethers of Schedule 
III anabolic steroids without the need to prove that these salts, 
esters, or ethers promote muscle growth.
	Removal of the automatic scheduling of isomers of steroids 
listed as Schedule III anabolic steroids.
	Addition of dehydroepiandrosterone to the list of excluded 
substances.
FDA Unveils New Package Insert Format
On January 18, 2006, FDA unveiled a major revision to the 
format of prescription drug information, commonly called the 
package insert, which will give health care professionals clear 
and concise prescribing information. This new format was 
developed in order to manage the risks of medication use and 
reduce medical errors; the new package insert will provide 
the most up-to-date information in an easy-to-read format. 
This new format will also make prescription information more 
accessible for use with electronic prescribing tools and other 
electronic information resources.
Revised for the first time in more than 25 years, the new format 
requires that the prescription information for new and recently 
approved products meet specific graphical requirements and 
includes the reorganization of critical information so physicians 
can find the information they need quickly. Some of the more 
important changes include:
	A new section called Highlights to provide immediate access 
to the most important prescribing information about benefits 
and risks.
	A table of contents for easy reference to detailed safety and 
efficacy information.
	The date of initial product approval, making it easier to deter-
mine how long a product has been on the market.
	A toll-free number and Internet reporting information for sus-
pected adverse events to encourage more widespread reporting 
of suspected side effects.
This new format will be integrated into FDA’s other e-
Health initiatives and standards-settings through a variety of 
ongoing initiatives at FDA. For more information please visit 
www.fda.gov/cder/regulatory/physLabel/default.htm.
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 Answer: No. Chapter 91 of the Acts of 2005 does not 
mandate parental consent for teens to obtain EC from 
a pharmacist or pharmacy. The law does not prevent a 
teen from involving her parent.
7. Question: What should a pharmacist do if a pharmacy 
customer discloses that the need for EC results from 
sexual assault?
 Answer: Observe the following best practice 
suggestion(s).
Provide standard medication screening and offer phar-
maceutical counseling consistent with M.G.L.§ 94C § 21A 
and 247 CMR 9.07. If a patient reports no contraindications, 
dispense medication per a standing order or, if customer 
presents a prescription, per the prescription. 
Provide appropriate referrals:
 For medical treatment and care, refer the pharmacy 
customer to a local rape crisis center and/or hospital 
emergency department. 
 For nearest Rape Crisis Center, visit www.mass.gov/dph/
fch/sapss/sites.htm.
 For nearest MDPH-designated hospital emergency room 
that uses MDPH-certified sexual assault nurse examiners 
to collect forensic evidence, visit www.mass.gov/dph/fch/
sane/index.htm
For confidential rape crisis counseling, refer pharmacy 
customer to the state’s confidential rape crisis hotline: 
 For hotline numbers, see: www.mass.gov/dph/fch/sapss/
sites.htm.
 For the statewide Spanish Language Helpline, call Llá-
manos: 1/800-223-5001.
Note: Under Massachusetts law, information transmitted 
in confidence by and between a victim of sexual assault 
and a sexual assault counselor including all information 
received by the sexual assault counselor that arises out of 
and in the course of such counseling shall not be subject to 
discovery and shall be inadmissible in any criminal or civil 
proceeding without the prior written consent of the victim 
to whom the report, record, working paper or memorandum 
relates. See M.G.L. c. 233 §20J. The statutory definition for 
“sexual assault counselor” does not include a pharmacist 
and the statutory privilege codified in §20J does not apply 
to pharmacy conversations or records maintained by the 
pharmacist.
8. Question: Are additional MDPH materials available to 
pharmacists and health care providers?
 Answer: Not at this time. 
Some materials are posted on the MDPH and the Board 
of Registration in Pharmacy Web sites. 
MDPH is preparing a pharmacist toolkit that is anticipated 
to contain other information for participating pharmacists. 
Check the MDPH and the Board of Registration in Pharmacy 
Web sites for forthcoming materials. 
Standing Order and Physician Practice
9. Question: How will a physician know that a particular 
standing order has been filed with the Board of Registra-
tion in Pharmacy and is ready for use? 
 Answer: Observe the following best practice 
suggestion(s).
Best practice(s): 
 Send the standing order via certified mail with return 
receipt requested in order to track delivery and receipt 
of the order. (The Board will not provide alternative 
written or oral confirmation of receipt of the standing 
order on file.)
 On each standardized order transmitted to the Board, 
include (1) the effective date and (2) the date that the 
order is transmitted to the Board for filing.
10. Question: Does a physician need to verify that a phar-
macist has been trained before signing a standing order 
with that pharmacist?
 Answer: Generally, no but a physician may wish to 
verify training before signing a standing order. 
Under M.G.L. c. 94C §19(A), pharmacists must complete 
requisite training before dispensing EC per a standing order. 
Board Policy No. 2006-1 requires that proof of training must 
be on file (readily retrievable) at the pharmacy.
State law does not require or prohibit a physician from 
seeking to verify that an individual pharmacist has completed 
training before signing a standing order. 
Nothing prohibits a licensed physician from providing 
a licensed pharmacy with a standing order that is signed 
and dated in advance of the date that an individual phar-
macist working at such pharmacy completes requisite 
training, so long as there are adequate personnel and 
management systems in place at the pharmacy for use of 
the standing order. A pharmacist commencing employ-
ment at a pharmacy that has a standing order on file for 
use by trained pharmacists may dispense EC pursuant 
to the standing order provided that such pharmacist has 
completed requisite training.
11. Question: If a physician signs an order authorizing all 
qualified pharmacists practicing at a pharmacy located 
at one particular location to dispense per the physician’s 
standing order and one of the pharmacists who works 
at that pharmacy also works at another pharmacy loca-
tion that does not have a standing order on file, can the 
pharmacist “carry” the standing order from location to 
location so as to “transfer” the physician’s standing order 
to different location(s) that do not have a standing order 
on file?
 Answer: No. 
See Frequently Asked Questions for pharmacists 
(Question No. 3 on page 5).
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Board Policy No. 2006-1 specifies that a copy of the stand-
ing order must be maintained on file (readily retrievable) at 
each participating pharmacy site.
If the physician’s standing order is written to authorize a 
specific individual pharmacist to dispense per the standing 
order at any pharmacy where he or she practices, copies of 
the standing order must be on file at each pharmacy location 
where such pharmacist practices.
12. Question: Will it still be necessary for physicians to 
write prescriptions for EC now that Plan B may be 
available at some pharmacies via a standing order?
 Answer: Yes.
Nothing in the new law limits or otherwise changes a 
physician’s authority to write a prescription for Plan B or 
other prescription medication.  
 It is not certain that an individual patient in need of EC 
will be able to obtain EC medication from a pharmacy 
without a prescription. Access under the new state law 
is contingent on a number of factors including, but not 
limited to: (1) pharmacies “opting in” to dispense under 
a standing order, and (2) a pharmacist with the requisite 
qualifications and training being available and ready to 
serve a pharmacy customer who arrives without a written 
prescription.
 In cases where a treating physician (or pharmacist acting 
under a standing order) determines in his or her profes-
sional judgment that Plan B is contraindicated but another 
prescription medication is necessary, a prescription is 
required.
 In cases where a patient under the physician’s care seeks 
a prescription that can be filled and refilled in the future 
(eg, while traveling if contraceptive method fails), the 
best practice for ensuring access to EC is to give the 
patient a prescription.
13. Question: The MDPH model standing order asks the 
physician to “List Pharmacy or Corporate Entity.”
A. Does this mean that a physician can authorize 
all pharmacists who work at a particular location 
(eg, pharmacy ABC located at 123 Washington 
Street,Town T, MA)? 
B. Can a physician use a standing order to authorize a 
corporate entity that operates a  chain of pharmacies 
(eg, to the ABC Corporation  that owns and operates 
20 licensed pharmacies in one or more geographic 
locations in the Commonwealth)?  
Answers to 13A and 13B: Yes. 
The scope of the standing order is a matter that is left to 
the discretion of the physician signing the standing order.  A 
physician may sign a standing order that authorizes qualified 
pharmacists practicing at a particular pharmacy location or 
qualified pharmacists who are employed by a particular cor-
porate entity to dispense EC per his or her standing order. Or, 
a physician may choose to sign a standing order authorizing 
one particular pharmacist.
14. Question: Does a physician who authorizes dispensing 
per a standing order increase his or her risk of liability? 
 Answer: Participating physicians (and participating 
pharmacists) are advised to consult their legal counsel 
and/or insurance agent regarding risk management 
issues and adequacy of professional malpractice 
insurance.
15. Question: Is there increased liability for the physi-
cian if his or her standing order is written so as to 
authorize a participating pharmacist to dispense to 
pharmacy patients who report having sexual inter-
course within the  preceding 120-hour period of time 
if the physician and the pharmacist know that, for 
maximum effectiveness, EC should be administered 
as soon as possible and, if possible, within 72 hours 
of sexual intercourse?
 Answer: Participating physicians (and participating 
pharmacists) are advised to consult their legal counsel 
and/or insurance agent regarding risk management issues 
and liability issues. 
16. Question: Do new MDPH regulations found at 105 
CMR 130.1040 to 130.1043 regarding timely access to 
EC for rape survivors only apply to emergency depart-
ments of hospitals?
 Answer: Yes. 
Amendments to the MDPH hospital licensure regulations 
only apply to emergency departments of hospitals. 
17. Question: If a woman calls her doctor’s office in need 
of EC, does the new law (Chapter 91 of the Acts of 
2005) require her doctor or other licensed professionals 
in that medical practice to give the caller a prescrip-
tion or provide her with information on where she can 
obtain it?  
 Answer: No. 
The legislature did not change the physician’s authority to 
prescribe Plan B or other prescription medications for EC. 
The new statutory and regulatory requirements regard-
ing provision of EC for female rape victims only applies to 
hospital emergency departments. 
Other
18. Question: If I obtain EC from a pharmacist pursuant to 
a standing order, will MassHealth (Medicaid) or private 
insurance pay for it? Will insurance also pay if I request 
EC for the future, before I need to take it?
 Answer: The new law does not address matters related 
to insurance coverage and benefits.
Currently, MassHealth (Medicaid) provides coverage 
for EC. For questions regarding MassHealth coverage and 
benefits and applicable co-payment for physician visits and 
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for prescription medication, call the MassHealth Customer 
Service Center: 1-800/841-2900 (TTY: 1-800/497-4648 for 
people with partial or total hearing loss).
 Questions regarding private insurance products, cover-
age, and benefits should be addressed to your health 
insurance plan. 
19. Question: Who in MDPH handles questions regarding 
Pharmacy and Emergency Department access to EC?
Contact Information
 Public/Consumers: 
Fami ly  P lann ing  Program,  Karen  Ed lund : 
617/624-6012 
Sexual Assault Prevention and Survivor Services 
Program, Marci Diamond: 617/624-5457 
 Hospitals: 
Division of Health Care Quality, 617/753-8000 
 Pharmacists/Pharmacies: 
Board of Registration in Pharmacy, Chuck Young or J.D. 
Coffey: 1-800/414-0168 or 617/973-0954 
Drug Control Program, 617/983-6700
 Physicians/Providers:
Board of Registration in Medicine, Assistant General 
Counsel Robert Harvey: 617/654-9800
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